Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers

Infection Control and Hospital Epidemiology

Volumn 30, Issue 10, 2009, Pages 1000-1005

  Corey, Kathleen E ^a,e   Servoss, Julie C ^a,e   Casson, Deborah R ^a,e   Kim, Arthur Y ^b,e   Robbins, Gregory K ^b,e   Franzini, Jean ^a,d   Twitchell, Katherine ^a,d   Loomis, Susan C ^a,c   Abraczinskas, Diane R ^a,e   Terella, Adam M ^a,e   Dienstag, Jules L ^a,e   Chung, Raymond T ^a,d,e  

^a Gastrointestinal Unit

^b Infectious Diseases Unit

^c Hatfield Quality Meats   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE PERSONNEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INJECTION SITE IRRITATION; LEUKOPENIA; MAJOR CLINICAL STUDY; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE; OPEN STUDY; PILOT STUDY; RASH; THORAX PAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; BLOOD-BORNE PATHOGENS; HEALTH PERSONNEL; HEPACIVIRUS; HEPATITIS C; HUMANS; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; INTERFERON ALFA-2B; NEEDLESTICK INJURIES; OCCUPATIONAL EXPOSURE; PILOT PROJECTS; POLYETHYLENE GLYCOLS; POST-EXPOSURE PROPHYLAXIS; QUESTIONNAIRES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 70350037752     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/605718     Document Type: Article

References (23)

1. Chung H, Kudo M, Kumada T, et al. Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. J Gastroenterol 2003; 38:877-879.
2. Jagger J, Puro V, De Carli G. Occupational transmission of hepatitis C virus. JAMA 2002; 288:1469.
3. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003; 36:47-53.
4. Takagi H, Uehara M, Kakizaki S, et al. Accidental transmission of HCV and treatment with interferon. J Gastroenterol Hepatol 1998; 13:238-243.
5. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16:1109-1114.
6. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control 1995; 23:273-277.
7. Sartori M, La Terra G, Aglietta M, Manzin A, Navino C, Verzetti G. Transmission of hepatitis C via blood splash into conjunctiva. Scand J Infect Dis 1993; 25:270-271.
8. Ippolito G, Puro V, Petrosillo N, De Carli G, Micheloni G, Magliano E. Simultaneous infection with HIV and hepatitis C virus following occupational conjunctival blood exposure. JAMA 1998; 280:28.
9. U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50(RR-11):1-52.
10. Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997; 315:333-337.
11. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of bloodborne infections in health care workers. Clin Microbiol Rev 2000; 13:385-407.
12. Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173:822-828.
13. Sánchez-Quijano A, Pineda JA, Lissen E, et al. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1988; 331:1245-1249.
14. Alter MJ. Occupational exposure to hepatitis C virus: a dilemma. Infect Control Hosp Epidemiol 1994; 15:742-744.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
16. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
17. Hwang SJ, Lee SD, Lu RH, et al. Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol 2001; 65:505-509.
18. Corey KE, Ross AS, Wurcel A, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 2006; 4:1278-1282.
19. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88.
20. Delwaide J, Bourgeois N, Gerard C, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004; 20:15-22.
21. Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37:60-64. (Pubitemid 36042145)
22. Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39:1213-1219.
23. Sulkowski MS, Ray SC, Thomas DL. Needlestick transmission of hepatitis C. JAMA 2002; 287:2406-2413.